Trial · NCT05233358
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
NCT05233358, Not applicable, Unknown, The Central Hospital of Lishui City
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure. Trials, record NCT05233358. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05233358
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
- NCT number
- NCT05233358
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 176 participants, estimated
- Lead sponsor
- The Central Hospital of Lishui City
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib, Immune Checkpoint Inhibitors
- First posted
- 2022-02-10
- Last updated
- 2022-02-10
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival | The time from enrollment to tumor progression or death from any cause, whichever came first, measured in "months", assessed up to 2 years. | The 6-month, 1-year and 2-year progression-free survival rates were evaluated. |
| Secondary | Overall Survival | Time from enrollment to death from any cause, in "months", assessed up to 2 years. For patients who are still alive at the time of data analysis, overall survival is calculated based on the date when the patient is last known to be alive. | The survival rates were evaluated. |
| Secondary | To Tumor Untreatable Progression | The time interval between receiving HAIC or TACE and the patient's inability to receive further intra-arterial treatment, assessed up to 12 months. | End point of antitumor drug trial. |
| Secondary | Objective Response Rate | Proportion of patients who achieved complete remission (CR) or partial remission (PR) according to mRECIST criteria, assessed up to 12 months. | The 1-, 3-, 6-, and 12 months ORR were evaluated. |
| Secondary | Disease Control Rate | Proportion of patients with complete remission (CR), partial remission (PR), and stable disease (SD) according to mRECIST criteria, assessed up to 12 months. | The 1-, 3-, 6-, and 12 months DCR were evaluated. |
| Secondary | Duration of Overall Response | The time from the first assessment of the tumor as complete remission or partial remission to the first assessment as disease progression or death from any cause, assessed up to 12 months. | Evaluation index of clinical efficacy of anticancer drugs. |
| Secondary | The incidence of adverse events and serious adverse events | Every follow-up time, assessed up to 2 years. | Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05233358
GET https://conductscience.org/api/trials/v1/NCT05233358/registered